Details
Stereochemistry | ACHIRAL |
Molecular Formula | C5H14NO |
Molecular Weight | 104.1708 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Charge | 1 |
SHOW SMILES / InChI
SMILES
C[N+](C)(C)CCO
InChI
InChIKey=OEYIOHPDSNJKLS-UHFFFAOYSA-N
InChI=1S/C5H14NO/c1-6(2,3)4-5-7/h7H,4-5H2,1-3H3/q+1
Molecular Formula | C5H13NO |
Molecular Weight | 103.1628 |
Charge | 0 |
Count |
|
Stereochemistry | RACEMIC |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Optical Activity | NONE |
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/19906248Curator's Comment: description was created based on several sources, including
https://clinicaltrials.gov/ct2/show/NCT02669641 | https://clinicaltrials.gov/ct2/show/NCT01098383 | https://clinicaltrials.gov/ct2/show/NCT00720343 | https://www.ncbi.nlm.nih.gov/pubmed/15213044 | https://www.ncbi.nlm.nih.gov/pubmed/28152052
Sources: https://www.ncbi.nlm.nih.gov/pubmed/19906248
Curator's Comment: description was created based on several sources, including
https://clinicaltrials.gov/ct2/show/NCT02669641 | https://clinicaltrials.gov/ct2/show/NCT01098383 | https://clinicaltrials.gov/ct2/show/NCT00720343 | https://www.ncbi.nlm.nih.gov/pubmed/15213044 | https://www.ncbi.nlm.nih.gov/pubmed/28152052
CHOLINE is a basic constituent of lecithin that is found in many plants and animal organs. Choline was officially recognized as an essential nutrient by the Institute of Medicine in 1998.1 Its role in the body is complex. It is needed for neurotransmitter synthesis (acetylcholine), cell-membrane signaling (phospholipids), lipid transport (lipoproteins), and methyl-group metabolism (homocysteine reduction). It is the major dietary source of methyl groups via the synthesis of S-adenosylmethionine (AdoMet). At least 50 AdoMet-dependent reactions have been identified in mammals, and it is likely that the number is much higher. Choline is required to make the phospholipids phosphatidylcholine, lysophosphatidylcholine, choline plasmalogen, and sphingomyelin—essential components for all membranes. It plays important roles in brain and memory development in the fetus and appears to decrease the risk of the development of neural tube defects. The importance of choline in the diet extends into adulthood and old age. In a study of healthy adult subjects deprived of dietary choline, 77% of the men and 80% of the postmenopausal women developed signs of subclinical organ dysfunction (fatty liver or muscle damage). Less than half of premenopausal women developed such signs. Ten percent of the subjects studied developed fatty liver, muscle damage, or both when they consumed the Adequate Intake (AI) of choline. The damage was reversed when they consumed a high-choline diet. Plasma choline concentration has been found to vary in response to diet, decreasing approximately 30 percent in humans fed a choline-deficient diet for 3 weeks. Based on estimated dietary intakes and studies reporting liver damage with lower choline intakes, the Institute of Medicine, Food and Nutrition Board set the AI for choline at 425 milligrams/per day for women aged 19 and older, and 550 milligrams/per day for men aged 19 and older.
CNS Activity
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL220 Sources: https://www.ncbi.nlm.nih.gov/pubmed/9435905 |
3013.0 µM [IC50] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Palliative | GABAZOLAMINE Approved UseAlprazolam tablets are indicated for the management of anxiety disorder (a condition corresponding most closely to the APA Diagnostic and Statistical Manual (DSM-III-R) diagnosis of generalized anxiety disorder) or the short-term relief of symptoms of anxiety. Anxiety or tension associated with the stress of everyday life usually does not require treatment with an anxiolytic. |
|||
Primary | TRILIPIX Approved UseINDICATIONS AND USAGE Trilipix is a peroxisome proliferator-activated receptor (PPAR) alpha agonist
indicated as adjunctive therapy to diet to:
• Reduce TG in patients with severe hypertriglyceridemia (1.1).
• Reduce elevated LDL-C, Total-C, TG and Apo B, and to increase HDLC
in patients with primary hypercholesterolemia or mixed dyslipidemia
(1.2).
Limitations of Use: Fenofibrate at a dose equivalent to 135 mg of Trilipix did
not reduce coronary heart disease morbidity and mortality in patients with
type 2 diabetes mellitus (5.1). Launch Date2008 |
|||
Primary | TRILIPIX Approved UseINDICATIONS AND USAGE Trilipix is a peroxisome proliferator-activated receptor (PPAR) alpha agonist
indicated as adjunctive therapy to diet to:
• Reduce TG in patients with severe hypertriglyceridemia (1.1).
• Reduce elevated LDL-C, Total-C, TG and Apo B, and to increase HDLC
in patients with primary hypercholesterolemia or mixed dyslipidemia
(1.2).
Limitations of Use: Fenofibrate at a dose equivalent to 135 mg of Trilipix did
not reduce coronary heart disease morbidity and mortality in patients with
type 2 diabetes mellitus (5.1). Launch Date2008 |
|||
Primary | TRILIPIX Approved UseINDICATIONS AND USAGE Trilipix is a peroxisome proliferator-activated receptor (PPAR) alpha agonist
indicated as adjunctive therapy to diet to:
• Reduce TG in patients with severe hypertriglyceridemia (1.1).
• Reduce elevated LDL-C, Total-C, TG and Apo B, and to increase HDLC
in patients with primary hypercholesterolemia or mixed dyslipidemia
(1.2).
Limitations of Use: Fenofibrate at a dose equivalent to 135 mg of Trilipix did
not reduce coronary heart disease morbidity and mortality in patients with
type 2 diabetes mellitus (5.1). Launch Date2008 |
PubMed
Title | Date | PubMed |
---|---|---|
Gain of function mutation of the alpha7 nicotinic receptor: distinct pharmacology of the human alpha7V274T variant. | 1999 Feb 5 |
|
Folate nutriture alters choline status of women and men fed low choline diets. | 1999 Mar |
|
Animal models of steatosis. | 2001 |
|
Role of cholinergic mossy fibers in medial vestibular and prepositus hypoglossal nuclei in vestibular compensation. | 2001 |
|
Temporal lobe changes following radiation therapy: imaging and proton MR spectroscopic findings. | 2001 |
|
Biological properties and measurement of phospholipase D activation by ADP-ribosylation factor (ARF). | 2001 |
|
Glucocorticoid hypersecretion following intracerebroventricular injection of ethylcholine mustard aziridinium ion in rats. | 2001 |
|
In vivo 1H magnetic resonance spectroscopic measurement of brain glycine levels in nonketotic hyperglycinemia. | 2001 Apr |
|
Reproducibility of proton magnetic resonance spectroscopy imaging measurements of normal human hippocampus at 1.5 T: clinical implications. | 2001 Apr |
|
Lateralizing ability of single-voxel proton mr spectroscopy in hippocampal sclerosis: comparison with mr imaging and positron emission tomography. | 2001 Apr |
|
Overactivation of alpha-amino-3-hydroxy-5-methylisoxazole-4-propionate and N-methyl-D-aspartate but not kainate receptors inhibits phosphatidylcholine synthesis before excitotoxic neuronal death. | 2001 Apr |
|
Proton MR spectroscopy in clinical routine. | 2001 Apr |
|
Proton magnetic resonance spectroscopic imaging reveals differences in spinocerebellar ataxia types 2 and 6. | 2001 Apr |
|
A novel method to analyze betaine in chicken liver: effect of dietary betaine and choline supplementation on the hepatic betaine concentration in broiler chicks. | 2001 Feb |
|
Intestinal uptake of betaine in vitro and the distribution of methyl groups from betaine, choline, and methionine in the body of broiler chicks. | 2001 Feb |
|
Blocking pulmonary ICAM-1 expression ameliorates lung injury in established diet-induced pancreatitis. | 2001 Feb |
|
Effect of N-acetylcysteine treatment on NO2-impaired type II pneumocyte surfactant metabolism. | 2001 Feb |
|
The calcium-dependent [3H]acetylcholine release from synaptosomes of brown trout (Salmo trutta) optic tectum is inhibited by adenosine A1 receptors: effects of enucleation on A1 receptor density and cholinergic markers. | 2001 Feb 16 |
|
Increased thalamic N-acetylaspartate in male patients with familial bipolar I disorder. | 2001 Feb 28 |
|
Turnover of phosphatidylcholine in Saccharomyces cerevisiae. The role of the CDP-choline pathway. | 2001 Feb 9 |
|
Three-dimensional magnetic resonance spectroscopic imaging of histologically confirmed brain tumors. | 2001 Jan |
|
1H MR spectroscopy evidence for the varied nature of asymptomatic focal brain lesions in neurofibromatosis type 1. | 2001 Jan |
|
Protein kinase C activation by 12-0-tetradecanoylphorbol 13-acetate in CG-4 line oligodendrocytes stimulates turnover of choline and ethanolamine phospholipids by phospholipase D and induces rapid process contraction. | 2001 Jan |
|
Improving diagnostic yield in brain biopsy: coupling spectroscopic targeting with real-time needle placement. | 2001 Jan |
|
Plasma choline in normal newborns, infants, toddlers, and in very-low-birth-weight neonates requiring total parenteral nutrition. | 2001 Jan |
|
Temporal lobe epilepsy: qualitative reading of 1H MR spectroscopic images for presurgical evaluation. | 2001 Jan |
|
Nicotinic agonists stimulate acetylcholine release from mouse interpeduncular nucleus: a function mediated by a different nAChR than dopamine release from striatum. | 2001 Jan |
|
Agmatine uptake by cultured hamster kidney cells. | 2001 Jan 12 |
|
Overexpression of a mammalian ethanolamine-specific kinase accelerates the CDP-ethanolamine pathway. | 2001 Jan 19 |
|
Light-induced reorganization of phospholipids in rod disc membranes. | 2001 Jan 26 |
|
The characteristics of nucleobase transport and metabolism by the perfused sheep choroid plexus. | 2001 Jan 5 |
|
Helicobacter pylori-induced prostaglandin E(2) synthesis involves activation of cytosolic phospholipase A(2) in epithelial cells. | 2001 Jan 5 |
|
Characterization of the deg-3/des-2 receptor: a nicotinic acetylcholine receptor that mutates to cause neuronal degeneration. | 2001 Mar |
|
The puzzle of zmpB and extensive chain formation, autolysis defect and non-translocation of choline-binding proteins in Streptococcus pneumoniae. | 2001 Mar |
|
Expression of the INO2 regulatory gene of Saccharomyces cerevisiae is controlled by positive and negative promoter elements and an upstream open reading frame. | 2001 Mar |
|
Sustained bilateral hemodynamic benefit of contralateral carotid endarterectomy in patients with symptomatic internal carotid artery occlusion. | 2001 Mar |
|
Evaluation of accumulated mucopolysaccharides in the brain of patients with mucopolysaccharidoses by (1)H-magnetic resonance spectroscopy before and after bone marrow transplantation. | 2001 Mar |
|
The biochemical analysis of neurotransmitters in central neurocytomas. | 2001 May |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://clinicaltrials.gov/ct2/show/NCT01098383
Choline tablets will be taken at daily doses of 250 mg (in children with up to 40 kg body weight) and 500 mg (in children with more than 40 kg body weight).
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/28152052
Monolayer cultures of Primary bovine hepatocytes were maintained for 24 h and were approximately 80% confluent before exposure to treatment. Cells were randomly assigned to increasing concentrations (61, 128, 2028, and 4528 μmol/L) of choline chloride (CC), DL-methionine (DLM), and a fatty acid cocktail in a 4X4X2 factorial arrangement. All treatments were applied in triplicate in independent preparations of cells from 4 Holstein calves.
Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 17:45:05 GMT 2025
by
admin
on
Mon Mar 31 17:45:05 GMT 2025
|
Record UNII |
N91BDP6H0X
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Systematic Name | English | ||
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
LIVERTOX |
NBK548710
Created by
admin on Mon Mar 31 17:45:05 GMT 2025 , Edited by admin on Mon Mar 31 17:45:05 GMT 2025
|
||
|
DSLD |
39 (Number of products:4095)
Created by
admin on Mon Mar 31 17:45:05 GMT 2025 , Edited by admin on Mon Mar 31 17:45:05 GMT 2025
|
||
|
NCI_THESAURUS |
C1551
Created by
admin on Mon Mar 31 17:45:05 GMT 2025 , Edited by admin on Mon Mar 31 17:45:05 GMT 2025
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
15354
Created by
admin on Mon Mar 31 17:45:05 GMT 2025 , Edited by admin on Mon Mar 31 17:45:05 GMT 2025
|
PRIMARY | |||
|
SUB13349MIG
Created by
admin on Mon Mar 31 17:45:05 GMT 2025 , Edited by admin on Mon Mar 31 17:45:05 GMT 2025
|
PRIMARY | |||
|
SUB20877
Created by
admin on Mon Mar 31 17:45:05 GMT 2025 , Edited by admin on Mon Mar 31 17:45:05 GMT 2025
|
ALTERNATIVE | |||
|
m3481
Created by
admin on Mon Mar 31 17:45:05 GMT 2025 , Edited by admin on Mon Mar 31 17:45:05 GMT 2025
|
PRIMARY | Merck Index | ||
|
N91BDP6H0X
Created by
admin on Mon Mar 31 17:45:05 GMT 2025 , Edited by admin on Mon Mar 31 17:45:05 GMT 2025
|
PRIMARY | |||
|
CHOLINE
Created by
admin on Mon Mar 31 17:45:05 GMT 2025 , Edited by admin on Mon Mar 31 17:45:05 GMT 2025
|
PRIMARY | |||
|
62-49-7
Created by
admin on Mon Mar 31 17:45:05 GMT 2025 , Edited by admin on Mon Mar 31 17:45:05 GMT 2025
|
PRIMARY | |||
|
D002794
Created by
admin on Mon Mar 31 17:45:05 GMT 2025 , Edited by admin on Mon Mar 31 17:45:05 GMT 2025
|
PRIMARY | |||
|
2449
Created by
admin on Mon Mar 31 17:45:05 GMT 2025 , Edited by admin on Mon Mar 31 17:45:05 GMT 2025
|
PRIMARY | RxNorm | ||
|
DB00122
Created by
admin on Mon Mar 31 17:45:05 GMT 2025 , Edited by admin on Mon Mar 31 17:45:05 GMT 2025
|
PRIMARY | |||
|
C61674
Created by
admin on Mon Mar 31 17:45:05 GMT 2025 , Edited by admin on Mon Mar 31 17:45:05 GMT 2025
|
PRIMARY | |||
|
100000080081
Created by
admin on Mon Mar 31 17:45:05 GMT 2025 , Edited by admin on Mon Mar 31 17:45:05 GMT 2025
|
PRIMARY | |||
|
305
Created by
admin on Mon Mar 31 17:45:05 GMT 2025 , Edited by admin on Mon Mar 31 17:45:05 GMT 2025
|
PRIMARY | |||
|
3097
Created by
admin on Mon Mar 31 17:45:05 GMT 2025 , Edited by admin on Mon Mar 31 17:45:05 GMT 2025
|
PRIMARY | |||
|
200-535-1
Created by
admin on Mon Mar 31 17:45:05 GMT 2025 , Edited by admin on Mon Mar 31 17:45:05 GMT 2025
|
PRIMARY | |||
|
DTXSID8043789
Created by
admin on Mon Mar 31 17:45:05 GMT 2025 , Edited by admin on Mon Mar 31 17:45:05 GMT 2025
|
PRIMARY | |||
|
N91BDP6H0X
Created by
admin on Mon Mar 31 17:45:05 GMT 2025 , Edited by admin on Mon Mar 31 17:45:05 GMT 2025
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
PARENT -> CONSTITUENT ALWAYS PRESENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT |
|
||
|
PARENT -> CONSTITUENT ALWAYS PRESENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT |
|
||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT |
|
||
|
PARENT -> CONSTITUENT ALWAYS PRESENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
TARGET -> AGONIST |
|
||
|
TRANSPORTER -> SUBSTRATE | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
PARENT -> CONSTITUENT ALWAYS PRESENT |
Amine found in Acorus calamus rhizome.
|
||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT |
|
||
|
SALT/SOLVATE -> PARENT |
Related Record | Type | Details | ||
---|---|---|---|---|
|
METABOLITE -> PARENT | |||
|
PARENT -> METABOLITE INACTIVE |
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> IMPURITY |
CHROMATOGRAPHIC PURITY (TLC)
EP
|
||
|
PARENT -> IMPURITY |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
|